Hypothyroidism Pharmacotherapy

Therapeutic selection

Levothyroxine (T4) has a longer effective duration than liothyronine (T3) and is generally used as the main replacement treatment. T4 is converted to T3 in peripheral tissues. Combination T4/T3 products require careful consideration; persistent symptoms alone do not establish a need for T3 supplementation.

Establish whether hypothyroidism is primary, central, treatment-related, or transient before applying the same laboratory follow-up to every patient. A history of pituitary disease or a discordance between free T4 and TSH is a reason to reassess interpretation rather than automatically escalating T4 based on TSH alone.

Why levothyroxine remains the reference treatment

Levothyroxine replaces circulating T4, allowing peripheral conversion to T3; its long half-life makes once-daily administration and steady-state titration practical. Routine combination T4/T3 therapy has not consistently demonstrated superior clinically meaningful outcomes. Desiccated thyroid products and T3-containing regimens have different pharmacokinetics and introduce avoidable peaks in susceptible patients. Persisting fatigue after biochemical normalization should trigger evaluation for sleep, anemia, depression, medication effects, and other causes rather than an automatic increase in thyroid hormone (Katz, 2026).

Identify the disease mechanism first. A high TSH with low FT4 supports primary overt hypothyroidism; low FT4 with an inappropriately normal or low TSH suggests central hypothyroidism. In central hypothyroidism, TSH does not reliably reflect dose adequacy, so treatment monitoring requires FT4 and specialist assessment, including evaluation of possible concomitant adrenal insufficiency before starting replacement (Katz, 2026).

Safety sequencing: in suspected central hypothyroidism, assess adrenal reserve or provide appropriate specialist-directed glucocorticoid coverage before initiating or substantially increasing levothyroxine if concomitant adrenal insufficiency is possible. Increasing metabolic clearance of cortisol with thyroid replacement can expose an unrecognized cortisol deficit and precipitate adrenal crisis. In central disease, the free T4 concentration, clinical status, and other pituitary deficits guide treatment rather than TSH alone (Katz, 2026).

Elevated TSH with normal free T4 represents mild (subclinical) hypothyroidism rather than overt hormone deficiency. Repeat testing and review transient illness, medications, anti-thyroid peroxidase antibodies, goiter, symptoms, age, cardiovascular disease, and pregnancy considerations. Persistent TSH elevation, particularly above approximately 10 mIU/L, or clinically important risk factors increases the rationale for treatment; a marginal elevation with normal free T4 does not necessarily justify immediate lifelong treatment. Treatment decisions should reflect repeat findings and patient context rather than a single result (Katz, 2026).

Initial dose and titration

A healthy patient without coronary disease and an older adult with known ischemic heart disease may require different starting intensity. A cautious initial approach may use lower doses in older patients or those with cardiovascular disease; specific starting amounts and titration should be individualized rather than automatically applying a single dose to every adult.

Dose decisions should reflect age, cardiac status, residual thyroid function, severity and chronicity, pregnancy, medication interactions, and actual adherence. Palpitations, angina, insomnia, tremor, and unintended weight changes can signal excess thyroid hormone activity. In vulnerable patients, overly rapid dose increases can precipitate cardiac symptoms.

Full replacement versus cautious initiation

For an otherwise healthy, younger adult with overt primary hypothyroidism, an approximate full replacement estimate is 1.6 mcg/kg/day, adjusted for factors such as body size, remaining thyroid function, and clinical risk. At 70 kg the arithmetic estimate is 112 mcg/day; this figure is not automatically appropriate for an older adult, someone with coronary artery disease, or a patient with longstanding severe disease. Such patients may begin at 12.5–25 mcg/day with more cautious adjustments (Katz, 2026).

In primary hypothyroidism, the long half-life of T4 means that TSH generally should be reassessed about 6–8 weeks after a dose or formulation change, rather than after a few days. Before increasing levothyroxine for unexpectedly high TSH, check missed doses, product substitution, timing with meals, calcium or iron supplementation, proton pump inhibitors, other interacting medications, and changes in gastrointestinal absorption. High-dose biotin can interfere with some thyroid immunoassays, and discordant results warrant a laboratory-method review. In central hypothyroidism, TSH does not reliably guide replacement; free T4 and the clinical picture are central to monitoring. Avoid rapid escalation in coronary disease or older adults because overtreatment can provoke arrhythmia, ischemia, and bone loss (Katz, 2026).

Administration and absorption

Consistency of administration is essential. Levothyroxine is commonly taken consistently on an empty stomach before breakfast. Oral iron, antacids, and bile acid sequestrants are specifically identified as agents that can decrease absorption. When TSH rises unexpectedly, determine how the patient takes the medication before labeling the dose inadequate.

Ask about missed doses, switching formulations, food timing, new supplements, medication changes, gastrointestinal illness, and pharmacy substitutions. If dose adjustments have repeatedly failed, reassess the diagnosis and potential malabsorption or adherence issues.

Why a stable dose may suddenly fail

Ask the patient to describe exactly how levothyroxine is taken: time of day, food, coffee, iron, calcium, antacids, bile-acid binding drugs, multivitamins, and proton-pump inhibitors. These factors can change absorption. Consistent administration and separation from calcium and iron; for some patients a liquid or gel-capsule formulation can be considered when absorption is persistently problematic.

Product substitution is not necessarily clinically insignificant. Maintain consistency of the dispensed formulation when feasible and repeat thyroid testing following a switch. Use micrograms in prescriptions and patient teaching; confusing milligrams with micrograms is a high-consequence error.

Interaction case: bile acid sequestrants and levothyroxine

Colesevelam can bind levothyroxine in the gastrointestinal tract and decrease its absorption. For interacting oral levothyroxine formulations, U.S. labeling recommends administering levothyroxine at least four hours before colesevelam, or monitoring thyroid function when timing cannot be reliably separated. If TSH rises after adding a bile acid sequestrant, verify the specific product, timing, and adherence before increasing the thyroid dose. After correcting the interaction, reassess thyroid function using the normal interval for levothyroxine equilibration (Levothyroxine sodium tablets, 2026; Katz, 2026).

Monitoring and treatment response

An unexpected TSH result: separate dose failure from testing error

A patient with previously stable primary hypothyroidism develops an increased TSH after starting iron supplementation. Before increasing levothyroxine, verify consistent product and dose, missed doses, timing with meals, and interactions that interfere with absorption. Where an interfering agent is responsible, correct administration and reassess after an appropriate interval rather than adding unnecessary thyroid hormone exposure.

If TSH and free T4 are discordant, assess whether the patient has pituitary disease, severe nonthyroidal illness, or assay interference. TSH alone is not a reliable titration target in central hypothyroidism; free T4 and clinical context carry greater weight. High-dose biotin may interfere with selected thyroid immunoassays. An unexpected value should prompt a laboratory and supplement review before treatment changes.

After an actual levothyroxine product switch, TSH is generally reassessed after approximately six weeks and retitrating if needed. In a patient with possible untreated adrenal insufficiency, assess and address cortisol deficiency before initiating thyroid replacement because increased metabolic demand can precipitate clinical deterioration. (Katz, 2026; Polomoff et al., 2026).

Clinical situation	Interpretation and follow-up
Primary hypothyroidism after a dose change	Measure TSH approximately 6–8 weeks after a levothyroxine dose or product change; review symptoms, administration, interactions, and the appropriateness of further adjustment.
Stable primary hypothyroidism	TSH and clinical assessment approximately every 6–12 months when clinically stable, with earlier testing if symptoms, pregnancy status, medication exposure, or product changes alter requirements (Katz, 2026).
Possible central hypothyroidism	TSH may not reliably represent replacement adequacy; review free T4 and pituitary context.
Symptoms suggest excessive replacement	Check TSH/free T4 as appropriate and assess cardiovascular symptoms and bone-risk context.
Unexpectedly elevated TSH	Verify administration, interacting agents, missed doses and product changes before escalating.

Interpreting underreplacement and overreplacement

For stable primary hypothyroidism, TSH with clinical review about every 6–12 months is a common maintenance approach. Recheck approximately 6–8 weeks after a meaningful dose or product change and monitor sooner when clinical circumstances require it. Signs of overreplacement include palpitations, heat intolerance, tremor, insomnia, and unexplained weight loss; underreplacement may present with persistent fatigue, cold intolerance, constipation, and slowed activity, but symptoms are nonspecific.

When TSH and symptoms disagree, do not reflexively chase a symptom score with more T4. Verify the laboratory context, medications, adherence, and other diagnoses. In central disease, reassessment centers on FT4 and pituitary context rather than the usual TSH target.

Do not chase laboratory numbers without context

A patient taking levothyroxine may be experiencing excess replacement when palpitations, tremor, anxiety, insomnia or unintended weight changes appear. Older adults and those with coronary disease or osteoporosis deserve particular attention to the consequences of excess hormone. The laboratory plan should address whether the problem is primary hypothyroidism or central disease, because TSH interpretation differs.

Interpret unexpected results before changing the dose

TSH and free T4 may be discordant during severe illness, with central hypothyroidism, after recent dose adjustments, or in the presence of assay interference. Ask about biotin supplements and the timing of blood sampling relative to thyroid medication; changing the dose to correct a spurious laboratory result can produce true hormone excess or deficiency. Nonthyroidal illness typically reflects altered thyroid hormone metabolism and signaling during systemic disease; routine thyroid replacement is not indicated solely to normalize transient low T3 in acute illness (Katz, 2026).

Quantify the pregnancy-related change without losing the monitoring plan

In patients taking levothyroxine for established hypothyroidism, the 2026 ATA guideline supports dose assessment and often an increase when pregnancy is confirmed, followed by individualized titration. For example, two additional 100-mcg tablets weekly increase a 100-mcg daily regimen from 700 to 900 mcg/week (about 29%). Most patients require roughly 25% more by gestational week 12 and 50% more by week 20, but requirements vary. A standardized increase may cause overtreatment when prepregnancy TSH is below 1.5 mU/L or the existing dose exceeds 100 mcg/day. Obtain prompt thyroid testing and reassess approximately every four weeks during early pregnancy, tailoring treatment to the response. For newly identified subclinical hypothyroidism, base treatment on gestational timing, persistent TSH elevation, and shared decision-making. TPOAb positivity informs etiologic assessment but is not itself an indication for levothyroxine under the 2026 guideline (Korevaar et al., 2026).

When TSH changes after a product switch, review whether the actual dispensed formulation changed, as well as administration with iron, calcium, prenatal vitamins, bile-acid sequestrants, or food. In primary disease, TSH generally requires about six to eight weeks after a dose or product change to equilibrate; in central hypothyroidism, free T4 rather than TSH must guide replacement. Suspected concurrent central adrenal insufficiency requires assessment before initiating thyroid hormone.

A change in dispensed levothyroxine formulation can alter thyroid hormone exposure even when the prescribed microgram amount is unchanged. Confirm the product and dispensing history before labeling a new TSH abnormality as progression. For primary hypothyroidism, recheck TSH approximately 6–8 weeks after a dose or product change; stable patients generally require less frequent surveillance, often every 6–12 months (Katz, 2026).

Special populations

Older adults, patients with coronary disease, and individuals with elevated fracture risk need particular vigilance for overtreatment. Pediatric hypothyroidism affects growth and neurologic development and warrants age-specific care. Referral is reasonable for pregnancy, suspected pituitary disease, complex treatment failure, and clinically significant heart disease.

Pregnancy and cardiac disease

In pregnancy, maintain a coordinated thyroid monitoring plan rather than treating an empiric dose increase as the end of management. Reassess TSH about every four weeks during the first half of pregnancy, at least once later in gestation, and after relevant dose changes. Iron- or calcium-containing prenatal supplements can interfere with levothyroxine absorption, so consistent separation is important. After delivery, many patients with established hypothyroidism can return toward the prepregnancy dose with a thyroid-function check around six weeks postpartum; patients treated solely for gestational or subclinical disease may require a different reassessment or trial of discontinuation. Cardiac risk, age, and symptoms of overreplacement remain clinically relevant (Korevaar et al., 2026; Katz, 2026).

In coronary artery disease, cautious initiation and slower titration reduce the risk of provoking angina or arrhythmia. In older adults, avoid unnecessarily suppressing TSH because excessive replacement can increase atrial fibrillation and skeletal risk. Suspected myxedema coma is a medical emergency requiring hospital-based IV therapy and evaluation of other endocrine deficiencies rather than routine outpatient escalation.

TSH suppression after differentiated thyroid cancer

Levothyroxine may be prescribed not only as physiologic replacement but also to suppress TSH after selected differentiated thyroid cancers. The appropriate target depends on tumor recurrence risk and treatment response and is set with the oncology/endocrinology team, not by defaulting to the usual hypothyroid TSH range. Over-suppression increases potential cardiovascular and skeletal harms, especially atrial arrhythmia and bone loss. This is an intentional specialist-directed exception to ordinary thyroid replacement rather than routine care for primary hypothyroidism (Katz, 2026).

Suspected pituitary disease changes the safety sequence

Low free T4 with an inappropriately low or normal TSH suggests central hypothyroidism rather than ordinary primary thyroid failure. Review the history for pituitary surgery, mass lesions, radiation, and other pituitary deficits. Concurrent adrenal insufficiency is a critical safety consideration: thyroid hormone can increase the metabolic demand for cortisol and may precipitate deterioration when glucocorticoid deficiency has not been addressed. Coordinate endocrine evaluation and establish adrenal safety before routine levothyroxine titration (Katz, 2026; Polomoff et al., 2026).

The subsequent laboratory target also changes. In central disease, TSH may remain low or uninformative even with appropriate replacement; free T4, clinical response, and the overall pituitary picture become more useful. This differs from primary hypothyroidism, where TSH usually guides maintenance adjustment.

Applied decisions

Case: Unexpectedly elevated TSH on an unchanged dose

A patient reports taking levothyroxine every morning with an iron tablet. Review the timing and medication list, establish a consistent administration approach, and repeat thyroid studies after an appropriate interval before assuming loss of thyroid function or prescribing a higher dose.

Case: Palpitations after rapid titration

An older adult with coronary disease develops palpitations after a large levothyroxine increase. Evaluate promptly for excess replacement and cardiovascular stress; normalizing a laboratory value is not the sole measure of safe treatment.

Case: Low free T4 with inappropriately normal TSH

A patient with prior pituitary surgery has low free T4 but non-elevated TSH. Consider central hypothyroidism and avoid applying an isolated TSH-based titration pathway. Further endocrine evaluation is appropriate.

Patient education: precise administration and pregnancy planning

Have the patient demonstrate the exact timing of levothyroxine relative to breakfast, coffee, iron, calcium, antacids, and prenatal vitamins. Calcium and iron can substantially impair absorption; the U.S. Synthroid tablet label instructs administration at least four hours apart from these agents. Apply the instructions for the dispensed formulation and use a consistent routine before judging the need for a dose increase. A patient who becomes pregnant should seek prompt thyroid testing and dose assessment, with repeated surveillance during pregnancy. Palpitations, tremor, or new cardiac symptoms warrant assessment for overreplacement (AbbVie Inc., 2024; Korevaar et al., 2026; Katz, 2026).

High-yield distinctions

Distinguish primary from central hypothyroidism before interpreting treatment response. Absorption, drug interactions, pregnancy, and excessive replacement can explain a changing thyroid profile without a new primary thyroid disorder.

Related YourDNP Resources

Pharmacology hub · Hypothyroidism · Hyperthyroidism pharmacotherapy · Adrenal insufficiency pharmacotherapy · Growth hormone pharmacotherapy

---

---

References

AbbVie Inc. (2024). Synthroid (levothyroxine sodium) tablets [Prescribing information]. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021402s038lbl.pdf

Katz, M. D. (2026). Thyroid disorders. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., pp. 1420–1454). McGraw Hill.

Korevaar, T. I. M., Leung, A. M., Alexander, E. K., Bliddal, S., Boelaert, K., Brenta, G., Chou, R., Dhillon-Smith, R., Dosiou, C., Eaton, J. L., Guan, H., Kilpatrick, S. J., Lasserre, B. J., Lee, S. Y., Maraka, S., Meister, K. D., Morris-Wiseman, L. F., Nguyen, C. T., Pearce, E. N., & Shan, Z. (2026). American Thyroid Association 2026 guidelines for thyroid disease in preconception, pregnancy, and postpartum. Thyroid, 36(5), 481–544. https://doi.org/10.1177/10507256261445624

Levothyroxine sodium tablets [Prescribing information]. (2026). DailyMed. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=633b3f9c-9578-4e07-a515-aec1a8b65e92

Polomoff, C. M., Chen, J. T., & Dang, D. K. (2026). Adrenal gland disorders. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., pp. 1455–1489). McGraw Hill.